NO20090158L - Composition comprising naproxen nanoparticles and controlled release hydrocarbon - Google Patents

Composition comprising naproxen nanoparticles and controlled release hydrocarbon

Info

Publication number
NO20090158L
NO20090158L NO20090158A NO20090158A NO20090158L NO 20090158 L NO20090158 L NO 20090158L NO 20090158 A NO20090158 A NO 20090158A NO 20090158 A NO20090158 A NO 20090158A NO 20090158 L NO20090158 L NO 20090158L
Authority
NO
Norway
Prior art keywords
composition
hydrocodone
combination
controlled release
bimodal
Prior art date
Application number
NO20090158A
Other languages
Norwegian (no)
Inventor
Gurvinder Singh Rekhi
Gary Liversidge
Scott Jenkins
John Devane
Niall Fanning
Paul Stark
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20090158L publication Critical patent/NO20090158L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelsen gjelder sammensetninger som omfatter en nanopartikulær naproksensammensetning i kombinasjon med en multipartikulær hydrokodonsammensetning for modifisert frigivelse som etter administrering til en pasient tilfører et hydrokodon på en bimodal eller multimodal måte. Den multipartikulære sammensetningen for modifisert frigivelse omfatter en første bestanddel og minst én påfølgende bestanddel hvor den første bestanddelen omfatter en første populasjon av hydrokodonholdige partikler og den minst ene påfølgende bestanddelen omfatter en andre populasjon av hydrokodonholdige partikler, hvori kombinasjonen av bestanddelene gir en bimodal eller multimodal frigivelsesprofil. Oppfinnelsen gjelder også en fast oral doseringsform som omfatter en slik kombinasjonssammensetning.The present invention relates to compositions comprising a nanoparticulate naproxen composition in combination with a modified release multiparticulate hydrocodone composition which, after administration to a patient, supplies a hydrocodone in a bimodal or multimodal manner. The modified release multiparticulate composition comprises a first component and at least one subsequent component wherein the first component comprises a first population of hydrocodone-containing particles and the at least one subsequent component comprises a second population of hydrocodone-containing particles, wherein the combination of the components provides a bimodal or multimodal release profile. . The invention also relates to a solid oral dosage form comprising such a combination composition.

NO20090158A 2006-06-23 2009-01-12 Composition comprising naproxen nanoparticles and controlled release hydrocarbon NO20090158L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81588506P 2006-06-23 2006-06-23
PCT/US2007/072052 WO2007150074A2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone

Publications (1)

Publication Number Publication Date
NO20090158L true NO20090158L (en) 2009-03-20

Family

ID=38834446

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090158A NO20090158L (en) 2006-06-23 2009-01-12 Composition comprising naproxen nanoparticles and controlled release hydrocarbon

Country Status (12)

Country Link
EP (1) EP2032137A2 (en)
JP (1) JP2009541359A (en)
KR (1) KR20090024284A (en)
CN (1) CN101484170A (en)
AU (1) AU2007260821B2 (en)
BR (1) BRPI0713447A2 (en)
CA (1) CA2660649A1 (en)
IL (1) IL196065A0 (en)
MX (1) MX2008016223A (en)
NO (1) NO20090158L (en)
WO (1) WO2007150074A2 (en)
ZA (1) ZA200810221B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
EP2826467B1 (en) 2010-12-22 2017-08-02 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
KR101794032B1 (en) * 2011-09-21 2017-11-07 (주)바이오시네틱스 Method for preparing nanoparticles
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
CN105120846B (en) 2013-02-05 2019-10-18 普渡制药公司 Tamper-Resistant Pharmaceutical Formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3355865B8 (en) 2015-09-29 2025-02-19 Merz Pharmaceuticals, LLC Sustained release compositions of 4-aminopyridine
CN112500694B (en) * 2020-12-04 2022-03-29 东莞威赢高尔夫用品有限公司 Electronic equipment veneer material and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
CA2348871C (en) * 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
US7713551B2 (en) * 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions

Also Published As

Publication number Publication date
CN101484170A (en) 2009-07-15
MX2008016223A (en) 2009-01-19
AU2007260821A1 (en) 2007-12-27
BRPI0713447A2 (en) 2012-03-13
JP2009541359A (en) 2009-11-26
KR20090024284A (en) 2009-03-06
WO2007150074A2 (en) 2007-12-27
IL196065A0 (en) 2009-09-01
ZA200810221B (en) 2009-11-25
EP2032137A2 (en) 2009-03-11
CA2660649A1 (en) 2007-12-27
AU2007260821B2 (en) 2012-06-21
WO2007150074A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
NO20090119L (en) Composition comprising controlled release nanoparticulated meloxicam and hydrocodone
WO2007150074A3 (en) Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
CY1125077T1 (en) TREATMENT OF VITAMIN D DEFICIENCY AND DEFICIENCY WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3
CL2011001131A1 (en) Use of a formulation that serves to prepare a drug for an injection, which minimizes inflammation at the site of injection of an antibody, and where the formulation comprises a 2h7 antibody and variants of the antibody and polyvinylpyrrolidone (pvp)
CL2009000171A1 (en) Compounds derived from 1-oxa-3-azaspiro, antagonists of the neuropeptide y5 receptor y (npy); pharmaceutical composition comprising said compound; and use for the treatment of eating disorders, drinking disorders, obesity, and depression.
CL2007003604A1 (en) Pharmaceutical composition for oral administration comprising the amorphous 17-aminogeldanamycin compound; and its use in the treatment of cancer.
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
ATE469895T1 (en) CGRP RECEPTOR ANTAGONISTS
CL2007003299A1 (en) COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE HEPATITIS C VIRUS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C.
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UA96308C2 (en) Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof
UA99284C2 (en) P70 s6 kinase inhibitors
CL2010000188A1 (en) A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
SG157415A1 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
WO2010116282A8 (en) 4, 5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
WO2009047644A3 (en) Method of treating vitamin d insufficiency and deficiency
DK1748756T3 (en) Compositions comprising molecularly dispersed drospirenone
SG171649A1 (en) Dpp iv inhibitor formulations
EA201001253A1 (en) N, N-DESIGNED AMINOALKYLBIPHENYLES AS ANTAGONISTS OF PROSTAGLANDIN RECEPTORS D
WO2010042652A3 (en) Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
CL2011000976A1 (en) Compounds derived from isonicotinamide and carboxamide, orexin receptor antagonists; pharmaceutical composition that includes them; and its use for the prevention of a sleep disorder.
NO20070785L (en) Compositions for the delivery of heavily water-soluble drugs.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application